Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients

Neuropediatrics

Volumn 35, Issue 2, 2004, Pages 95-98

  Artuch, Rafael ^a,b   Aracil, A ^a   Mas, A ^a   Monros E ^a   Vilaseca, M A ^a   Pineda, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Cerebrospinal fluid; Friedreich ataxia; Idebenone; Ubiquinone 10

Indexed keywords

ANTIOXIDANT; IDEBENONE; QUINONE DERIVATIVE; UBIDECARENONE;

ADOLESCENT; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; FRIEDREICH ATAXIA; HUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIOXIDANTS; BENZOQUINONES; BLOOD-BRAIN BARRIER; CASE-CONTROL STUDIES; CHILD; FRIEDREICH ATAXIA; HUMANS; UBIQUINONE;

EID: 2442495100     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815830     Document Type: Article

References (21)

1. Artuch R, Aracil A, Mas A, Colome C, Rissech M, Monros E et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 2002; 33: 190-193
2. Buyse G, Mertens L, Di Salvo G, Matthijs I, Weidemann F, Eyskens B et al. Idebenone treatment in Friedreich's ataxia. Neurological, cardiac, and biochemical monitoring. Neurology 2003; 60: 1679-1681
3. Colomé C, Artuch R, Vilaseca MA, Sierra C, Brandi N, Lambruschini N et al. Lipophilic antioxidants in phenylketonuric patients. Am J Clin Nutr 2003; 77: 185-188
4. 10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57: 515-518
5. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195-204
6. Gabsi S, Gouider-Khouja N, Belal S, Fki M, Kefi M, Turki I et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur J Neurol 2001; 8: 477-481
7. Gillis JC, Benefield P, McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 1994; 5: 133-152
8. Grieb P, Ryba MS, Debicki GS, Gordon-Krajcer W, Januszeswski S, Chrapusta SJ. Changes in oxidative stress in the rat brain during post-cardiac arrest reperfusion, and the effect of treatment with the free radical scavenger idebenone. Resuscitation 1998; 39: 107-113
9. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-1679
10. Nagai Y, Yoshida K, Narumi S, Tanayama S, Nagaoka A. Brain distribution of idebenone and its effects on local cerebral glucose utilization in rats. Arch Gerontol Geriatr 1989; 8: 257-272
11. Napolitano A, Salvetti S, Vista M, Lombardi V, Siciliano G, Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 2000; 21: 981-982
12. Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, Stebbins GT et al. Alpha-tocopherol in the ventricular cerbrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology 1996; 47: 1037-1042
13. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998; 70: 1781-1792
14. Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet 1995; 29: 110-129
15. Pisano P, Durand A, Autret E, Desnuelle C, Pinsard N, Serratrice G et al. Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. Eur J Clin Pharmacol 1996; 51: 167-169
16. Ricciarelli R, Zingg JM, Azzi A. Vitamin E: protective role of a Janus molecule. FASEB J 2001; 15: 2314-2325
17. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999; 354: 477-479
18. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U et al. Increased lipoprotein oxidation in Alzheimer's disease. Free Rad Res 2000; 28: 351-360
19. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K et al. International Cooperative Ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997; 145: 205-211
20. Vatassery GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 1998; 50: 1900-1902
21. Wakabayashi H, Nakajima M, Yamato S, Shimada K. Determination of idebenone in rat serum and brain by high-performance liquid chromatography using platinum catalyst reduction and electrochemical detection. J Chromatogr 1992; 573: 154-157